Study of Inflammatory Role of Epstein-Barr Virus (EBV) in Atrophic and Erosive Forms of Oral Lichen Planus

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02276573

Acronym

LICHENVIR

Enrollment

Registered

2014-10-28

Start date

2015-03-30

Completion date

2016-03-10

Last updated

2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lichen Planus, Oral

Brief summary

Oral lichen planus (OLP) is a chronic inflammatory and relapsing. The average prevalence is 1 to 4%. The clinics forms are many and symptoms are varied. The erosive form, painful and debilitating is characterized by erosive areas, ulcerated on an erythematous base with or without a keratinocyte lichenien network. The literature data moving towards an autoimmune origin, but the pathophysiological mechanisms of OLP remain unknown. This project represents the first part of a comprehensive project to examine the oral pathogenesis of different viruses (Herpes and papillomavirus HPV) and centered on Epstein-Barr Virus (EBV).

Interventions

BIOLOGICALbuccal cavity sample

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient ≥ 18 years * Clinical and/or histological diagnosis of erosive or atrophic OLP * No signs of severe dysplasia at the sampling

Exclusion criteria

o immunosuppressive or anti-inflammatory therapies at the inclusion

Design outcomes

Primary

Measure	Time frame
Measure of level of EBV nucleic acids	day 1

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026